SIS
NRIX icon

Sound Income Strategies’s Nurix Therapeutics NRIX Stock Holding History

Sound Income Strategies’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80
Closed -$1.24K – 1741
2026
Q1 		$1.24K Hold
80
– – ﹤0.01% 2257
2025
Q4 		$1.54K Buy
+80
New +$1.15K ﹤0.01% 2201

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sound Income Strategies's NRIX Position: Q2 2026 in Review

Sound Income Strategies sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 80 shares — an estimated $1.24K sold.

Sound Income Strategies first reported a position in NRIX in Q4 2025 and held it in 2 quarters. The position peaked at $1.54K in Q4 2025. 133 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Sound Income Strategies reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 80 Nurix Therapeutics shares in Q2 2026, an estimated $1.24K.
  • Sound Income Strategies first reported a position in Nurix Therapeutics in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's Nurix Therapeutics position peaked at $1.54K in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.